Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TNYA
Strong SellSinkerTenaya Therapeutics, Inc. · Healthcare · United States · $155M · Avg Vol: $1M/d
COMPANY DESCRIPTION
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering, developing, and delivering curative therapies for heart disease. Its competitive moat lies in its integrated product discovery platform that combines gene therapy, cellular regeneration, and precision medicine approaches for genetically defined cardiovascular conditions. Tenaya is a focused player in the burgeoning field of cardiovascular genetic medicines, aiming to transform the treatment paradigm for severe heart diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | 4.0M | 2.5M | — |
| EPS | -0.85 | -0.53 | -0.52 | -0.59 | — | -0.51 | -0.46 | -0.39 | — |
| Shares | 217.0M | 217.0M | 217.0M | 216.8M | -0.1% | 224.2M | — | — | — |
| Debt | 15.1M | 12.4M | 13.6M | 10.8M | -10.5% | 3.9M | — | — | — |
| Equity | 243.4M | 139.4M | 92.9M | 123.3M | -20.3% | — | — | — | — |
| Op CF | -104.4M | -102.1M | -90.5M | -68.3M | — | -52.3M | — | — | — |
| Inv CF | 83.7M | 48.7M | 1.1M | 56.1M | — | — | — | — | — |
| Fin CF | 77.8M | 4.0M | 47.7M | 108.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TNYA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TNYA | Tenaya Therapeutics, Inc.(you) | $155M | 14 | Strong Sell |
| LENZ | LENZ Therapeutics, Inc. | $161M | 14 | Strong Sell |
| OTLK | Outlook Therapeutics, Inc. | $156M | 14 | Strong Sell |
| INDP | Indaptus Therapeutics, Inc. | $152M | 13 | Strong Sell |
| SPRB | Spruce Biosciences, Inc. | $175M | 13 | Strong Sell |
| UNCY | Unicycive Therapeutics, Inc. | $144M | 12 | Strong Sell |
| KPTI | Karyopharm Therapeutics Inc. | $168M | 11 | Strong Sell |
| ANIX | Anixa Biosciences, Inc. | $118M | 14 | Strong Sell |
| CNTB | Connect Biopharma Holdings Limited | $140M | 10 | Strong Sell |
| VANI | Vivani Medical, Inc. | $128M | 11 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%